Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $40.3 million.

  • Mirum Pharmaceuticals' Change in Accured Expenses rose 90.92% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 28.73%. This contributed to the annual value of $40.3 million for FY2024, which is 30.98% up from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' Change in Accured Expenses is $40.3 million, which was up 30.98% from $30.8 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Change in Accured Expenses registered a high of $40.3 million during FY2024, and its lowest value of $3.7 million during FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Change in Accured Expenses had a median value of $30.8 million in 2023 and averaged $26.2 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Change in Accured Expenses skyrocketed by 515.12% in 2021 and then crashed by 66.28% in 2022.
  • Mirum Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $3.7 million in 2020, then soared by 515.12% to $22.7 million in 2021, then tumbled by 66.28% to $7.6 million in 2022, then spiked by 302.91% to $30.8 million in 2023, then surged by 30.98% to $40.3 million in 2024.